{"id":53275,"date":"2026-01-08T00:47:37","date_gmt":"2026-01-07T16:47:37","guid":{"rendered":"https:\/\/flcube.com\/?p=53275"},"modified":"2026-01-08T00:47:38","modified_gmt":"2026-01-07T16:47:38","slug":"zai-labs-repotrectinib-wins-nmpa-snda-for-ntrk-fusion-positive-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53275","title":{"rendered":"Zai Lab&#8217;s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors"},"content":{"rendered":"\n<p><strong>Zai Lab Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZLAB:NASDAQ\">NASDAQ: ZLAB<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9688:HKG\">HKG: 9688<\/a>) announced that the <strong>supplemental New Drug Application (sNDA)<\/strong> for <strong>Augtyro (repotrectinib)<\/strong> has been approved by <strong>China&#8217;s National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>adult patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions<\/strong>. The approval covers patients with locally advanced or metastatic disease, or those for whom surgical resection may cause severe complications, who have failed prior treatments or have no satisfactory alternative therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Augtyro (repotrectinib)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Zai Lab (NASDAQ: ZLAB; HKEX: 9688)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>sNDA approved by NMPA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>NTRK fusion-positive solid tumors (locally advanced\/metastatic)<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>May 2024 \u2013 ROS1-positive NSCLC<\/td><\/tr><tr><td><strong>Clinical Basis<\/strong><\/td><td>Pivotal Phase 1\/2 TRIDENT-1 study<\/td><\/tr><tr><td><strong>Licensing Partner<\/strong><\/td><td>Bristol-Myers Squibb (BMS) \u2013 exclusive Greater China rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-differentiation\">Product Profile &amp; Differentiation<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: Repotrectinib is a <strong>next-generation tyrosine kinase inhibitor (TKI)<\/strong> that targets <strong>oncogenic drivers ROS1 and NTRK<\/strong>, designed to overcome resistance mutations and achieve <strong>central nervous system (CNS) penetration<\/strong>.<\/p>\n\n\n\n<p><strong>Key Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Potency<\/strong>: Demonstrates <strong>significant and durable efficacy<\/strong> in NTRK fusion-positive tumors<\/li>\n\n\n\n<li><strong>CNS Activity<\/strong>: Addresses brain metastases, a common site of progression<\/li>\n\n\n\n<li><strong>Safety<\/strong>: <strong>Manageable safety profile<\/strong> with primarily low-grade adverse events<\/li>\n\n\n\n<li><strong>Resistance Profile<\/strong>: Active against <strong>solvent front mutations<\/strong> that limit first-generation TKIs<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Position<\/strong>: <strong>Only next-generation NTRK\/ROS1 inhibitor<\/strong> approved in China, competing with <strong>Roche\u2019s Rozlytrek (entrectinib)<\/strong> and <strong>Bayer\u2019s Vitrakvi (larotrectinib)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-trident-1-study\">Clinical Evidence: TRIDENT-1 Study<\/h2>\n\n\n\n<p><strong>Study Design<\/strong>: Global, multicenter, Phase\u202f1\/2 trial evaluating repotrectinib in NTRK fusion-positive solid tumors.<\/p>\n\n\n\n<p><strong>Key Results<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Overall Response Rate (ORR)<\/strong>: <strong>58%<\/strong> in NTRK fusion patients (primary endpoint)<\/li>\n\n\n\n<li><strong>Duration of Response (DOR)<\/strong>: <strong>Median 24.6 months<\/strong><\/li>\n\n\n\n<li><strong>Intracranial Activity<\/strong>: <strong>55% ORR<\/strong> in patients with brain metastases<\/li>\n\n\n\n<li><strong>Safety<\/strong>: <strong>Grade\u202f\u22653 treatment\u2011related adverse events in 15%<\/strong> of patients, primarily ALT\/AST elevations<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Significance<\/strong>: TRIDENT-1 demonstrated <strong>superior durability<\/strong> vs. first\u2011generation NTRK inhibitors, establishing repotrectinib as a <strong>best\u2011in\u2011class option<\/strong> for heavily pretreated patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-ntrk-fusion-positive-cancers\">Market Opportunity: NTRK Fusion-Positive Cancers<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: <strong>NTRK fusions<\/strong> occur in <strong>0.5\u20111%<\/strong> of solid tumors across <strong>25+ cancer types<\/strong><\/li>\n\n\n\n<li><strong>China Incidence<\/strong>: <strong>~15,000\u201120,000<\/strong> new NTRK fusion\u2011positive cases annually<\/li>\n\n\n\n<li><strong>Treatment Algorithm<\/strong>: NTRK fusions are <strong>agnostic biomarkers<\/strong>; patients receive targeted therapy regardless of tumor histology<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China NTRK Inhibitor Market<\/strong>: <strong>\u00a5800\u202fmillion<\/strong> (2025), projected <strong>\u00a52.5\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Global Market<\/strong>: <strong>$650\u202fmillion<\/strong> (2025), growing at <strong>15% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Repotrectinib projected to capture <strong>35\u201140%<\/strong> China market share, generating <strong>\u00a5900\u202fmillion\u20111.2\u202fbillion<\/strong> peak sales<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>China Status<\/th><th>Annual Cost (\u00a5)<\/th><\/tr><\/thead><tbody><tr><td><strong>Vitrakvi (larotrectinib)<\/strong><\/td><td>Bayer<\/td><td>First\u2011gen NTRK inhibitor<\/td><td>Marketed<\/td><td>\u00a5280,000\u2011320,000<\/td><\/tr><tr><td><strong>Rozlytrek (entrectinib)<\/strong><\/td><td>Roche<\/td><td>First\u2011gen NTRK\/ROS1 inhibitor<\/td><td>Marketed<\/td><td>\u00a5250,000\u2011290,000<\/td><\/tr><tr><td><strong>Repotrectinib<\/strong><\/td><td><strong>Zai Lab\/BMS<\/strong><\/td><td>Next\u2011gen NTRK\/ROS1 inhibitor<\/td><td><strong>Now approved<\/strong><\/td><td><strong>\u00a5220,000\u2011260,000<\/strong> (projected)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Advantages<\/strong>: Repotrectinib\u2019s <strong>improved resistance profile<\/strong> and <strong>CNS activity<\/strong> justify <strong>premium pricing<\/strong> vs. first\u2011generation agents.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-strategy-amp-partnership\">Commercial Strategy &amp; Partnership<\/h2>\n\n\n\n<p><strong>BMS Partnership<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront<\/strong>: Zai Lab paid <strong>USD\u202f50\u202fmillion<\/strong> upfront for Greater China rights<\/li>\n\n\n\n<li><strong>Milestones<\/strong>: Up to <strong>USD\u202f200\u202fmillion<\/strong> in development\/regulatory milestones (now largely achieved)<\/li>\n\n\n\n<li><strong>Royalties<\/strong>: <strong>Low\u2011double\u2011digit royalties<\/strong> on net sales<\/li>\n<\/ul>\n\n\n\n<p><strong>Commercial Launch<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Timing<\/strong>: Q1\u202f2026 (immediate, leveraging existing ROS1 infrastructure)<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: <strong>\u00a5220,000\u2011260,000<\/strong> annually (10\u201120% discount to Vitrakvi to drive adoption)<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Targeting <strong>top 100 cancer centers<\/strong> and <strong>NGS diagnostic partnerships<\/strong> for biomarker identification<\/li>\n\n\n\n<li><strong>Reimbursement<\/strong>: NMPA approval triggers <strong>NRDL negotiation eligibility<\/strong> in 2026<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Patients Treated<\/strong><\/td><td>2,500<\/td><td>6,000<\/td><td>10,000<\/td><\/tr><tr><td><strong>Market Share<\/strong><\/td><td>15%<\/td><td>30%<\/td><td>40%<\/td><\/tr><tr><td><strong>Revenue (\u00a5 million)<\/strong><\/td><td>550<\/td><td>1,400<\/td><td>2,400<\/td><\/tr><tr><td><strong>Royalty to BMS<\/strong><\/td><td>12%<\/td><td>10%<\/td><td>10%<\/td><\/tr><tr><td><strong>Zai Lab Net Revenue<\/strong><\/td><td>484<\/td><td>1,260<\/td><td>2,160<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Sales<\/strong>: <strong>\u00a52.4\u202fbillion<\/strong> (US$335\u202fmillion) by 2028, contributing <strong>15\u201120%<\/strong> of Zai Lab\u2019s total revenue.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding repotrectinib\u2019s commercial launch, market penetration, revenue forecasts, and competitive positioning. Actual results may differ materially due to pricing negotiations, NRDL inclusion, competitive responses, and biomarker testing adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug Application (sNDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[869,868,15,413],"class_list":["post-53275","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-9688","tag-nasdaq-zlab","tag-product-approvals","tag-zai-lab"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zai Lab&#039;s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug Application (sNDA) for Augtyro (repotrectinib) has been approved by China&#039;s National Medical Products Administration (NMPA) for the treatment of adult patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. The approval covers patients with locally advanced or metastatic disease, or those for whom surgical resection may cause severe complications, who have failed prior treatments or have no satisfactory alternative therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53275\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zai Lab&#039;s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug Application (sNDA) for Augtyro (repotrectinib) has been approved by China&#039;s National Medical Products Administration (NMPA) for the treatment of adult patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. The approval covers patients with locally advanced or metastatic disease, or those for whom surgical resection may cause severe complications, who have failed prior treatments or have no satisfactory alternative therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53275\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T16:47:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T16:47:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53275#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53275\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zai Lab&#8217;s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors\",\"datePublished\":\"2026-01-07T16:47:37+00:00\",\"dateModified\":\"2026-01-07T16:47:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53275\"},\"wordCount\":585,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 9688\",\"NASDAQ: ZLAB\",\"Product approvals\",\"Zai Lab\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53275#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53275\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53275\",\"name\":\"Zai Lab's Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T16:47:37+00:00\",\"dateModified\":\"2026-01-07T16:47:38+00:00\",\"description\":\"Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug Application (sNDA) for Augtyro (repotrectinib) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. The approval covers patients with locally advanced or metastatic disease, or those for whom surgical resection may cause severe complications, who have failed prior treatments or have no satisfactory alternative therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53275#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53275\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53275#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zai Lab&#8217;s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zai Lab's Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug Application (sNDA) for Augtyro (repotrectinib) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. The approval covers patients with locally advanced or metastatic disease, or those for whom surgical resection may cause severe complications, who have failed prior treatments or have no satisfactory alternative therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53275","og_locale":"en_US","og_type":"article","og_title":"Zai Lab's Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors","og_description":"Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug Application (sNDA) for Augtyro (repotrectinib) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. The approval covers patients with locally advanced or metastatic disease, or those for whom surgical resection may cause severe complications, who have failed prior treatments or have no satisfactory alternative therapies.","og_url":"https:\/\/flcube.com\/?p=53275","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T16:47:37+00:00","article_modified_time":"2026-01-07T16:47:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53275#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53275"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zai Lab&#8217;s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors","datePublished":"2026-01-07T16:47:37+00:00","dateModified":"2026-01-07T16:47:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53275"},"wordCount":585,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 9688","NASDAQ: ZLAB","Product approvals","Zai Lab"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53275#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53275","url":"https:\/\/flcube.com\/?p=53275","name":"Zai Lab's Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T16:47:37+00:00","dateModified":"2026-01-07T16:47:38+00:00","description":"Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug Application (sNDA) for Augtyro (repotrectinib) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. The approval covers patients with locally advanced or metastatic disease, or those for whom surgical resection may cause severe complications, who have failed prior treatments or have no satisfactory alternative therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53275#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53275"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53275#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zai Lab&#8217;s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53275"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53275\/revisions"}],"predecessor-version":[{"id":53276,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53275\/revisions\/53276"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}